Researchers study long-term safety of lentiviral gene therapy in primates, finding no evidence of somatic mutations or ...

While each cell contains the complete genetic blueprint of an organism, chemical marks on the DNA—so-called epigenetic ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.

Positive topline data from a phase 2 trial show HT-6184, an allosteric NEK7/NLRP3 inflammasome inhibitor, improves ...

Advances in peptide drug development and the rising prevalence of hematological disorders are driving demand for peptide-based therapeu ...

How do human organs develop and what happens to them when they become diseased? To answer these questions, researchers are ...

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion ...

Keros Therapeutics (KROS) announced that it presented additional data from its two ongoing Phase 2 clinical trials of ...

Biopharma leaders at companies developing blood cancer therapies say we shouldn’t be afraid to use the four-letter word: cure ...

Researchers at University of California San Diego School of Medicine and their colleagues have developed the first ...

Norika Liu 1,2,3 * Atsushi Nakano 2,3,4,5,6 This article addresses the ongoing controversies surrounding endocardial hematopoiesis and explores potential directions for future research in endocardial ...